当前期刊: Advances in Chronic Kidney Disease Go to current issue    加入关注   
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Breastfeeding and Medication Use in Kidney Disease
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-05-11
    Manisha Singh

    Pregnancy in chronic kidney disease is a condition fraught with challenges including multiple medications, high risk pregnancy followed by maternal and fetal compromise such as preterm delivery and low birth weight infant. Breastfeeding is unique in its impact on the mother and the baby, their bonding and future health implications impacting the society. Breastmilk is produced specific for the infant

    更新日期:2020-05-11
  • Fundaments of Toxicology—Approach to the Poisoned Patient
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Chiarra Ornillo; Nikolas Harbord

    Management of the poisoned patient begins with supportive care, assessment of organ function and dysfunction, and consideration of known or suspected poisons. The possibility of multiple ingestions should be considered with intentional exposures or suicide attempts. Enteric decontamination involves treatment to prevent the absorption of toxins from the gastrointestinal system and includes the use of

    更新日期:2020-04-20
  • Common Toxidromes and the Role of Extracorporeal Detoxification
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Nikolas Harbord

    Extracorporeal modalities have been used for detoxification for decades, with hemodialysis the preferred and most commonly used modality. Salicylates, lithium, methanol, and ethylene glycol are the most common poisonings treated with dialysis. For each of these common poisonings, a description of the toxidrome including pharmacokinetics, clinical presentation, an overview of treatment, and the role

    更新日期:2020-04-20
  • Toxicity of Metformin and Hypoglycemic Therapies
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Muhammad S. Akhter; Priyasha Uppal

    Metformin along with other antidiabetic medications provide benefit to patients in the treatment of type 2 diabetes mellitus, but caution is advised in certain scenarios to avoid toxicity in kidney disease. Renal dosing, monitoring of kidney function, and evaluating the risk of developing serious side effects are warranted with some agents. The available literature with regard to incidence of adverse

    更新日期:2020-04-20
  • Nephrotoxicity of Antimicrobials and Antibiotics
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Martha Catalina Morales-Alvarez

    Medication-induced nephrotoxicity remains one of the most common causes of acute kidney injury (AKI) among hospitalized patients. Within the extensive group of medications associated with AKI, antibiotics and other antimicrobials are well recognized triggers of structural and functional renal impairment. Clinical manifestations range from mild forms of tubular injury to significant deterioration of

    更新日期:2020-04-20
  • Nephrotoxic Chemotherapy Agents: Old and New
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Anthony Nicolaysen

    In the last several decades, advancements in chemotherapy have improved the overall survival of cancer patients. These agents, however, are associated with adverse effects, including various kidney lesions. This review summarizes the nephrotoxic potential of chemotherapy agents, old and new, as well as the different factors that contribute to kidney injury. Provided for each class of chemotherapy agent

    更新日期:2020-04-20
  • Radiocontrast Toxicity
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Staci Leisman

    Intravenous and intraarterial contrast media are invaluable tools in the diagnosis of anatomic lesions. However, they have been associated with deleterious renal events, ranging from acute kidney injury (iodinated contrast) to nephrogenic systemic fibrosis (gadolinium-containing agents). Contrast-associated acute kidney injury has a wide incidence, likely due to differences in populations studied,

    更新日期:2020-04-20
  • The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Samira S. Farouk; Joshua L. Rein

    Calcineurin inhibitors (CNIs) are both the savior and Achilles' heel of kidney transplantation. Although CNIs have significantly reduced rates of acute rejection, their numerous toxicities can plague kidney transplant recipients. By 10 years, virtually all allografts will have evidence of CNI nephrotoxicity. CNIs have been strongly associated with hypertension, dyslipidemia, and new onset of diabetes

    更新日期:2020-04-20
  • Toxicity of Herbs, Vitamins, and Supplements
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Elliot Charen; Nikolas Harbord

    In the United States, the Food and Drug Administration regulates the efficacy and safety of pharmaceutical drugs. This government agency was formed in direct response to a mass poisoning and more than 100 deaths from kidney failure due to a medicinal toxic alcohol exposure. In contrast, the Food and Drug Administration also regulates the use of vitamins, minerals, herbs, or botanicals as dietary supplements

    更新日期:2020-04-20
  • The Association of Mesalamine With Kidney Disease
    Adv. Chronic Kidney Dis. (IF 2.673) Pub Date : 2020-03-05
    Avinash Adiga; David S. Goldfarb

    The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: “renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine delayed-release tablets that contain mesalamine or are

    更新日期:2020-04-20